Applied Therapeutics’ stock price surged after the company received positive news from the FDA regarding its New Drug Application (NDA) review for govorestat, a potential treatment for Classic Galactosemia. The FDA has confirmed that an advisory committee meeting is no longer necessary, and the priority review of the NDA remains on track.